Arcadia Biosciences

RKDA

Capitalización de mercado USD 397 k

– Net cash used in operating activities only $319K in the second quarter – – Arcadia closes $4 million private placement; ends second quarter with $4.2 million in cash – – July monthly Zola ® sales top $740K; exceed $1 million through first week of August – DALLAS, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc .® (Nasdaq: RKDA), a producer and marketer of innovative wellness products, today released its financial and business results for the second quarter and first half of 2026.

DALLAS, June 12, 2026 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer of innovative wellness products, announced today the closing of its previously announced private placement priced at-the-market under Nasdaq rules for the purchase and sale of 3,883,496 shares of its common stock (or pre-funded warrants in lieu thereof), Series A-1 preferred investment options to purchase up to an aggregate of 3,883,496 shares of common stock and Series A-2 preferred investment options to purchase up to an aggregate of 3,883,496 shares of common stock at a purchase price of $1.03 per share of common stock (or pre-funded warrant in lieu thereof) and associated preferred investment options.

DALLAS, June 11, 2026 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc .® (Nasdaq: RKDA), a producer and marketer of innovative wellness products, announced today that it has entered into securities purchase agreements for the purchase and sale of 3,883,496 shares of its common stock (or pre-funded warrants in lieu thereof), Series A-1 preferred investment options to purchase up to an aggregate of 3,883,496 shares of common stock and Series A-2 preferred investment options to purchase up to an aggregate of 3,883,496 shares of common stock at a purchase price of $1.03 per share of common stock (or pre-funded warrant in lieu thereof) and associated preferred investment options in a private placement priced at-the-market under Nasdaq rules.

-- Zola ® volumes increase 18% year-over-year -- -- SG&A at lowest level in Arcadia's history -- DALLAS, May 14, 2026 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc .® (Nasdaq: RKDA), a producer and marketer of innovative wellness products, today released its financial and business results for the first quarter of 2026.

-- Zola ® revenues increase 17% year-over-year -- -- Arcadia and Roosevelt Resources terminate proposed business combination --

DALLAS, Jan. 12, 2026 (GLOBE NEWSWIRE) --  Arcadia Biosciences, Inc .® (Nasdaq: RKDA), a producer and marketer of innovative wellness products, today announced that it has entered into definitive agreements for the immediate exercise of certain outstanding preferred investment options to purchase up to an aggregate of 808,595 shares originally issued in December 2020, January 2021, August 2022 and March 2023, having an exercise price of $9.00 per share, at a reduced exercise price of $2.575 per share. The shares of common stock issuable upon exercise of the preferred investment options are registered pursuant to effective registration statements on Form S-1 (Registration Nos. 333-262407 and 333-267637) and Form S-3 (Registration Nos. 333-252659 and 333-271082). The gross proceeds to the company from the exercise of the preferred investment options are expected to be approximately $2.1 million, prior to deducting placement agent fees and offering expenses.

DALLAS, Dec. 26, 2025 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc .® (Nasdaq: RKDA), a producer and marketer of innovative wellness products, today announced that on December 24, 2025, it received a notice from Roosevelt Resources, LP, terminating the Securities Exchange Agreement between Arcadia and Roosevelt dated December 4, 2024, pursuant to the terms of the agreement. The agreement provided for a proposed business combination transaction between the two companies.

-- Zola ® year-to-date revenues increase 26% year over year -- -- Arcadia gross profit margins exceed 30% for 11 th straight quarter -- -- Arcadia cash balance declines by only $257K to $1.1M -- DALLAS, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc .® (Nasdaq: RKDA), a producer and marketer of innovative wellness products, today released its financial and business results for the third quarter of 2025.

Soybean-related stocks exploded on Wednesday following President Donald Trump's latest comments in the ongoing trade war with China.

-- Arcadia revenues increase 11% year over year driven by 24% growth in Zola ® -- -- Arcadia receives 2.7 million shares of stock in ABVE --